Role of Trientine in Hypertrophic Cardiomyopathy: A Review of Mechanistic Aspects
Open Access
- 14 September 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (9) , 1145
Abstract
Abnormality in myocardial copper homeostasis is believed to contribute to the development of cardiomyopathy. Trientine, a copper-chelating drug used in the management of patients with Wilson’s disease, demonstrates beneficial effects in patients with hypertrophic cardiomyopathy. This review aims to present the updated development of the roles of trientine in hypertrophic cardiomyopathy. The drug has been demonstrated in animal studies to restore myocardial intracellular copper content. However, its mechanisms for improving the medical condition remain unclear. Thus, comprehending its mechanistic aspects in cardiomyopathy is crucial and could help to expedite future research.Keywords
Funding Information
- Faculty of Medicine Fundamental Grant, Universiti Kebangsaan Malaysia (FF-2020-048)
- BHF Oxford CRE (RE/18/3/34214)
This publication has 84 references indexed in Scilit:
- Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic ratsCardiovascular Diabetology, 2013
- Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairmentCardiovascular Diabetology, 2013
- Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimerʼs DiseaseDrugs, 2011
- Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in ratsActa Pharmacologica Sinica, 2011
- Copper Transporter 2 Content Is Lower in Liver and Heart of Copper-Deficient RatsInternational Journal of Molecular Sciences, 2010
- The Metal Chelators, Trientine and Citrate, Inhibit the Development of Cardiac Pathology in the Zucker Diabetic RatExperimental Diabetes Research, 2009
- Role of Copper and Homocysteine in Pressure Overload Heart FailureCardiovascular Toxicology, 2008
- Reversal of diabetes‐evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)‐selective chelatorProteomics – Clinical Applications, 2007
- Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in miceJournal of Experimental Medicine, 2007
- Molecular Changes Evoked by Triethylenetetramine Treatment in the Extracellular Matrix of the Heart and Aorta in Diabetic RatsMolecular Pharmacology, 2006